Investors

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

Dec 8, 2019

Supporting Materials